Duopharma Biotech to produce second oncology medicine


Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.

Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma Biotech , oncology , cancer , healthcare

   

Next In Business News

Ringgit to trade in tight range of 4.46-4.48 versus US dollar next week
Building a firm facade
Portfolio positioning under Trump era
Singapore playing roulette with casino licensing
RHB, CGC in LCTF portfolio guarantee deal
Market struggles to find direction
Capitalising on future trade tariffs
Bidding big on Malaysian art
Inflation rises slightly in October
Shedding light on power sector prospects

Others Also Read